Pathophysiologic effects of uremic retention solutes

Journal of the American Society of Nephrology

Volumn 10, Issue 8, 1999, Pages 1815-1823

  Vanholder, Raymond ^a   De Smet, Rita ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; GUANIDINE; HOMOCYSTEINE; INDOLE; OXALIC ACID; PARA CRESOL; PARATHYROID HORMONE RECEPTOR; PHOSPHORUS; UNCLASSIFIED DRUG; UREA; UROFURAN ACID;

DETOXIFICATION; DIALYSIS; GLYCOSYLATION; INTESTINE ABSORPTION; KIDNEY CLEARANCE; KIDNEY FAILURE; MORBIDITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTAKE; REVIEW; UREMIA;

EID: 0032838784     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (137)

1. Vanholder R, De Smet R, Hsu C, Vogeleere P, Ringoir S: Uremic toxins: The middle molecule hypothesis revisited. Semin Nephrol 14: 205-218, 1994
2. Vanholder R, De Smet R, Vogeleere P, Hsu C, Ringoir S: The uraemic syndrome. In: Replacement of Renal Function by Dialysis, 4th Ed., edited by Jacobs C, Kjellstrand CM, Koch KM, Winchester JF, Kluwer Academic Publishers, Dordrecht, The Netherlands, 1996, pp 1-33
3. Vanholder R, Van Loo A, Dhondt AM, Glorieux G, De Smet R, Ringoir S: Second symposium on uremic toxicity: Summary of a symposium held in Gent, Belgium. Nephrol Dial Transplant 10: 414-418, 1995
4. Bergström J: Uremic toxicity. In: Nutritional Management of Renal Disease, edited by Kopple JD, Massry SG, Williams & Wilkins, Baltimore, 1997, pp 97-190
5. Ringoir S: An update on uremic toxins. Kidney Int 52[Suppl 62]: S2-S4, 1997
6. Charra B, Calemard E, Laurent G: Importance of treatment time and blood pressure control in achieving long-term survival on dialysis. Nephron 16: 35-44, 1996
7. Charra B, Calemard E, Ruffet M, Chazot C, Terrat JC, Vanel T, Laurent G: Survival as an index of adequacy of dialysis. Kidney Int 41: 1286-1291, 1992
8. Johnson WJ, Hagge WW, Wagoner RD, Dinapoli RP, Rosevear JW: Effects of urea loading in patients with far-advanced renal failure. Mayo Clin Proc 47: 21-29, 1972
9. Lim J, Gasson C, Kaji DM: Urea inhibits NaK2Cl cotransport in human erythrocytes. J Clin Invest 96: 2126-2132, 1995
10. Baudouin-Legros M, Asdram L, Tondelier D, Paulais M, Anagnostopoulos T: Extracellular urea concentration modulates cAMP production in the mouse MTAL. Kidney Int 50: 26-33, 1996
11. Monti JP, Brunet PJ, Berland YF, Vanuxem DC, Vanuxem PA, Crevat AD: Opposite effects of urea on hemoglobin-oxygen affinity in anemia of chronic renal failure. Kidney Int 48: 827-831, 1995
12. Prabhakar SS, Zeballos G, Montoya M, Leonard C: Urea inhibits inducible nitric oxide synthesis in murine macrophages at a post-transcriptional level [Abstract]. J Am Soc Nephrol 8: 24A, 1997
13. Vanholder RC, Ringoir SM: Editorial review. Adequacy of dialysis: A critical analysis. Kidney Int 42: 540-558, 1992
14. Owen WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329: 1001-1006, 1993
15. Blumenkrantz MJ, Kopple JD, Moran JK, Coburn JW: Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int 21: 849-861, 1982
16. Anderstam B, Mamouh AH, Södersten P, Bergström J: Middle-sized molecule fractions isolated from uremic ultrafiltrate and normal urine inhibit ingestive behavior in the rat. J Am Soc Nephrol 7: 2453-2460, 1996
17. Kamanna VS, Kashyap ML, Pai R, Bui DT, Jin FY, Roh DD, Shah GM, Kirschenbaum MA: Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line. J Am Soc Nephrol 5: 193-200, 1994
18. Andress DL, Howard GA, Birnbaum RS: Identification of a low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma. Kidney Int 39: 942-945, 1991
19. Hornberger JC, Chernew M, Petersen J, Garber AM: A multivariate analysis of mortality and hospital admissions with highflux dialysis. J Am Soc Nephrol 3: 1227-1237, 1992
20. Hakim RM, Held PJ, Stannard DC, Wolfe RA, Port FK, Daugirdas JT, Agodoa L: Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 50: 566-570, 1996
21. Chandran PKG, Liggett R, Kirkpatrick B: Patient survival on PAN/AN69 membrane hemodialysis: A ten year analysis. Kidney Int 43[Suppl 41]: S287-S290, 1993
22. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T: Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 52: 1096-1101, 1997
23. Jadoul M, Garbar C, Noël H, Sennesael J, Vanholder R, Bernaert P, Rorive G, Hanique G, van Ypersele de Strihou C: Histological prevalence of β2-microglobulin amyloidosis in hemodialysis: A prospective post-mortem study. Kidney Int 51: 1928-1932, 1997
24. 2,-microglobulin amyloidosis in CAPD patients compared with hemodialysis patients. Kidney Int 54: 956-959, 1998
25. 2-microglobulin is modified with N∈-(carboxymethyl)lysine in dialysis related amyloidosis. Kidney Int 50: 1303-1309, 1996
26. Miyata T, Ueda T, Shinzato T, Iida Y, Tanaka S, Kurokawa K, van Ypersele de Strihou C, Maeda K: Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 7: 1198-1206, 1996
27. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele de Strihou C: Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 51: 1170-1181, 1997
28. 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int 51: 187-194, 1997
29. Miyata T, Inagi R, Iida Y, Sato M, Yamada N, Oda O, Maeda K, Seo H: Involvement of β,-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 93: 521-528, 1994
30. 2-M) induces the release of MMP-1 and TIMP-1 from synovial fibroblasts [Abstract]. J Am Soc Nephrol 8: 227A, 1997
31. 2-microglobulin. Nephrol Dial Transplant 9: 382-388, 1994
32. Assounga A, Canaud B, Flavier JL, Slingeneyer A, Robinet-Levy M, Aznar R, Mion C: Que signifie la beta 2 microglobuline circulante chez les urémiques en traitement de suppléance? Néphrologie 8: 301-306, 1987
33. Mourad G, Argilés A: Renal transplantation relieves the symptoms but does not reverse β2-microglobulin amyloidosis. J Am Soc Nephrol 7: 798-804, 1996
34. Amann K, Wiest G, Mall G, Ritz E, Klaus G: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4: 1814-1819, 1994
35. Rao DS, Shih M, Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328: 171-175, 1993
36. Massry SG, Smogorzewski M: Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 14: 219-231, 1994
37. Massry SG, Smogorzewski M: Parathyroid hormone, chronic renal failure and the liver. Kidney Int 52[Suppl 62]: S5-S7, 1997
38. Smogorzewski M, Massry SG: Uremic cardiomyopathy: Role of parathyroid hormone. Kidney Int 52[Suppl 62]: S12-S14, 1997
39. Urena P, Kubrusly M, Mannstadt M, Hruby M, Trinh Trang Tan MM, Silve C, Lacour B, Abou-Samra AB, Segre GV, Drüeke T: The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int 45: 605-611, 1994
40. 2+]. Kidney Int 47: 1182-1186, 1995
41. Urena P, Mannstadt M, Hruby M, Ferreira A, Schmitt F, Silve C, Ardaillou R, Lacour B, Abou-Samra AB, Segre GV, Drücke T: Parathyroidectomy does not prevent the renal PTH/PTHrP receptor down-regulation in uremic rats. Kidney Int 47: 1797-1805, 1995
42. Ramirez JA, Goodman WG, Belin TR, Gales B, Segre GV, Salusky IB: Calcitriol therapy and calcium-regulated PTH secretion in patients with secondary hyperparathyroidism. Am J Physiol 267: E961-E967, 1994
43. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321, 1988
44. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP: Iinmunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 46: 216-222, 1994
45. Patel SR, Koenig RJ, Hsu CH: Effect of Schiff base formation on the function of the calcitriol receptor. Kidney Int 50: 1539-1545, 1996
46. Imani F, Horii Y, Suthanthiran M, Skolnik EY, Makita Z, Sharma V, Sehajpal P, Vlassara H: Advanced glycosylation end product-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: Role in tissue remodeling. J Exp Med 178: 2165-2172, 1993
47. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 87: 432-438, 1991
48. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49: 1304-1313, 1996
49. Yong Ming Li, Tan AX, Vlassara H: Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat Med 1: 1057-1061, 1995
50. Abel M, Ritthaler U, Zhang Y, Deng Y, Schmidt AM, Greten J, Sernau T, Wahl P, Andrassy K, Ritz E, Waldherr R, Stern DM, Nawroth PP: Expression of receptors for advanced glycosylated end-products in renal disease. Nephrol Dial Transplant 10: 1662-1667, 1995
51. Monnier VM, Sell DR, Nagaraj RH, Miyata S, Grandhee S, Odetti P, Ibrahim SA: Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 41[Suppl 2]: 36-41, 1992
52. Lamb EJ, Cattell WR, Dawnay AB: In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Kidney Int 47: 1768-1774, 1995
53. Hörl WH, Haag-Weber M, Georgopoulos A, Block LH: Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells. Proc Natl Acad Sci USA 87: 6353-6357, 1990
54. Haag-Weber M, Mai B, Hörl WH: Impaired cellular host defence in peritoneal dialysis by two granulocyte inhibitory proteins. Nephrol Dial Transplant 9: 1769-1773, 1994
55. Tschesche H, Kopp C, Hörl WH, Hempelmann U: Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment. J Biol Chem 269: 30274-30280, 1994
56. Cohen J, Rudnicki M, Hörl WH: Isolation of modified ubiquitin as a neutrophil chemotaxis inhibitor from uremic patients. J Am Soc Nephrol 9: 451-456, 1998
57. Kabanda A, Jadoul M, Pochet JM, Lauwerys R, van Ypersele de Strihou C, Bernard A: Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis. Kidney Int 45: 1689-1696, 1994
58. 2-inhibitor protein. J Clin Invest 92: 2099-2109, 1993
59. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F: Effects of the obese gene produce on body weight regulation in ob/ob mice. Science 269: 540-543, 1995
60. Haalas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM: Weight-reduction effects of the plasma protein encoded by the obese gene. Science 269: 543-546, 1995
61. Sharma K, Considine RV, Michael B, Dunn SR, Weisberg LS, Kurnik BRC, Kurnik PB, O'Connor J, Sinha M, Caro JF: Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 51: 1980-1985, 1997
62. Young GA, Woodrow G, Kendall S, Oldroyd B, Turney JH, Brownjohn AM, Smith MA: Increased plasma leptin/fat ratio in patients with chronic renal failure: A cause of malnutrition? Nephrol Dial Transplant 12: 2318-2323, 1997
63. Johansen K, Mulligan K, Tai V, Shambelan M: Leptin, body composition and indices of malnutrition in dialysis patients [Abstract]. J Am Soc Nephrol 8: 195A, 1997
64. Heimbürger O, Lönnqvist F, Danielsson A, Nordenström J. Stenvinkel P: Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 8: 1423-1430, 1997
65. De Deyn PP, MacDonald RL: Guanidino compounds that are increased in uremia inhibit GABA and glycine responses on mouse neurons in cell culture. Ann Neurol 28: 627-633, 1990
66. D'Hooge R, Pei YQ, Marescau B, De Deyn PP: Convulsive action and toxicity of uremic guanidino compounds: Behavioral assessment and relation to brain concentration in adult mice. J Neurol Sci 112: 96-105, 1992
67. Weisensee D, Löw-Friedrich I, Riehle M, Bereiter-Hahn J, Schoeppe W: In vitro approach to "uremic cardiomyopathy." Nephron 65: 392-400, 1993
68. Yokozawa T, Fujitsuka N, Oura H, Akao T, Kobashi K, Ienaga K, Nakamura K, Hattori M: Purification of methylguanidine synthase from the rat kidney. Nephron 63: 452-457, 1993
69. Hiravama A, Noronha Dutra AA, Gordge MP, Neild GH, Hothersall JS: Mechanism of inhibition by guanidino compounds on neutrophil superoxide production [Abstract]. J Am Soc Nephrol 8: 238A, 1997
70. Asaka M, Iida H. Izumino K, Sasayama S: Depressed natural killer cell activity in uremia. Nephron 49: 291-295, 1988
71. MacAllister RJ, Whitley GS, Vallance P: Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int 45: 737-742, 1994
72. White R, Barefield D, Ram S, Work J: Peritoneal dialysis solutions reverse the hemodynamic effects of nitric oxide synthesis inhibitors. Kidney Int 48: 1986-1993, 1995
73. Rees DD, Palmer RM, Moncada S: Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 86: 3375-3378, 1989
74. Baylis C, Mitruka B, Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90: 278-281, 1992
75. Liew FY, Millott S, Parkinson C, Palmer RM, Moncada S: Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 144: 4794-4797, 1990
76. Johns RA, Moscicki JC, Difazio CA: Nitric oxide synthase inhibitor dose-dependently and reversibly reduces the threshold for halothane anesthesia: A role for nitric oxide in mediating consciousness? Anesthesiotogy 77: 779-784, 1992
77. Faraci FM, Brian JE, Heistad DD: Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 269: H1522-H1527, 1995
78. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E: Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 11: 2449-2452, 1997
79. G-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 8: 1437-1442, 1997
80. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ: Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 15: 901-909, 1997
81. Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, Yasukawa H, Iwami G, Okuda S, Imaizumi T: Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 29: 242-247, 1997
82. Sorrentino R, Pinto A: Effect of methylguanidine on rat blood pressure: Role of endothelial nitric oxide synthase. Br J Pharmacol 115: 510-514, 1995
83. Noris M, Benigni A, Boccardo P, Aiello Q, Gaspari F, Todeschini M, Figliuzzi M, Remuzzi G: Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension. Kidney Int 44: 445-450, 1993
84. Levillain O, Marescau B, De Deyn PP: Guanidino compound metabolism in rats subjected to 20% to 90% nephrectomy. Kidney Int 47: 464-472, 1995
85. Marangella M, Petrarulo M, Cosseddu D, Vitale C, Linari F: Oxalate balance studies in patients on hemodialysis for type 1 primary hyperoxaluria. Clin Sci 19: 546-553, 1992
86. Marangella M, Vitale C, Petrarulo M, Tricerri A, Cerelli E, Cadario A, Portigliatti Barbos M, Linari F: Bony content of oxalate in patients with primary hyperoxaluria or oxalosis-unrelated renal failure. Kidney Int 48: 182-187, 1995
87. Salyer WR, Hutchins GM: Cardiac lesions in secondary oxalosis. Arch Intern Med 134: 250-252, 1974
88. Abuelo JG, Schwartz ST, Reginato AJ: Cutaneous oxalosis after long-term hemodialysis. Arch Intern Med 152: 1517-1520, 1992
89. Marangella M, Vitale C, Petrarulo M, Cosseddu D, Gallo L, Linari F: Pathogenesis of severe hyperoxalemia in Crohn's disease-related renal failure on maintenance haemodialysis: Successful management with pyridoxine. Nephrol Dial Transplant 7: 960-964, 1992
90. Marangella M, Bagnis C, Bruno M, Petrarulo M, Gabella P, Linari F: Determinants of oxalate balance in patients on chronic peritoneal dialysis. Am J Kidney Dis 21: 419-426, 1993
91. Wolfson M, Cohen AH, Kopple JD: Vitamin B-6 deficiency and renal function and structure in chronic uremic rats. Am J Clin Nutr 53: 935-942, 1991
92. Morgan SH, Maher ER, Purkiss P, Watts RWE, Curtis JR: Oxalate metabolism in end-stage renal disease: The effect of ascorbic acid and pyridoxine. Nephrol Dial Transplant 3: 28-32, 1988
93. Coburn JW, Salusky IB: Control of serum phosphorus in uremia. N Engl J Med 320: 1140-1142, 1989
94. Combe C, Aparicio M: Phosphorus and protein restriction and parathyroid function in chronic renal failure. Kidney Int 46: 1381-1386, 1994
95. Llach F: Secondary hyperparathyroidism in renal failure: The trade-off hypothesis revisited. Am J Kidney Dis 25: 663-679, 1995
96. Imanishi Y, K'oyama H, Inaba M, Okuno S, Nishizawa Y, Morii H, Otani S: Phosphorus intake regulates intestinal function and polyamine metabolism in uremia. Kidney Int 49: 499-505, 1996
97. Loghman-Adham M: Role of phosphate retention in the progression of renal failure. J Lab Clin Med 122: 16-26, 1993
98. Schiller LR, Santa Ana CA, Sheikh MS, Emmett M, Fordtran JS: Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 320: 1110-1113, 1989
99. Niwa T: Phenol and p-cresol accumulated in uremic serum measured by HPLC with fluorescence detection. Clin Chem 39: 108-111, 1993
100. Thompson DC, Perera K, Fisher R, Brendel K: Cresol isomers: Comparison of toxic potency in rat liver slices. Toxicol Appl Pharmacol 125: 51-58, 1994
101. Goodhart PJ, De Wolf WE, Kruse LI: Mechanism-based inactivation of dopamine β-hydroxylase by p-cresol and related alkylphenols. Biochemistry 26: 2576-2583, 1987
102. Lascelles PT, Taylor WH: The effect upon tissue respiration in vitro of metabolites which accumulate in uraemic coma. Clin Sci 31: 403-413, 1966
103. MacNamara PJ, Lalka D, Gibaldi M: Endogenous accumulation products and serum protein binding in uremia. J Lab Clin Med 98: 730-740, 1981
104. Yokoyama MT, Tabori C, Mimmer ER, Hogberg MG: The effect of antibiotics in the weanling pig diet on the growth and the excretion of volatile phenolic and aromatic bacterial metabolites. Am J Clin Nutr 35: 1417-1424, 1982
105. Heipieper HJ, Keweloh H, Rehm HJ: Influence of phenols on growth and membrane permeability of free and immobilized Escherichia coli. Appl Environ Microbiol 57: 1213-1217, 1991
106. Vanholder R, De Smet R, Waterloos MA, Van Landschoot N, Vogeleere P, Hoste E, Ringoir S: Mechanisms of the uremic inhibition of phagocyte reactive species production: Characterization of the role of p-cresol. Kidney Int 47: 510-517, 1995
107. Abreo K, Sella M, Gautreaux S, De Smet R, Vogeleere P, Ringoir S, Vanholder R: p-Cresol and phenol increase the uptake and toxicity of aluminum in cultured mouse hepatocytes. J Am Soc Nephrol 6: 935-942, 1997
108. De Smet R, Glorieux G, Vanholder R: p-Cresol and uric acid: Two old uremic toxins revisited. Kidney Int 52[Suppl 62]: S8-S11, 1997
109. Anderson IB, Mullen WH, Meeker JE, Khojasteh-Bakht SC, Oishi S, Nelson SD, Blanc PD: Pennyroyal toxicity: Measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med 124: 726-734, 1996
110. Niwa T, Ise M, Miyazaki T, Meada K: Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats. Nephron 65: 82-87, 1993
111. Perna AF, Ingrosso D, De Santo NG, Galletti P, Zappia V: Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 47: 247-253, 1995
112. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I: Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 324: 1149-1155, 1991
113. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 274: 1049-1057, 1995
114. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268: 877-881, 1992
115. Bostom AG, Shemin D, Lapane KL, Miller JW, Sutherland P, Nadeau M, Seyoum E, Hartman W, Prior R, Wilson PWF, Selhub J: Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study. Atherosclerosis 114: 93-103, 1995
116. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, Vigo P, Mayer EL, Selhub J, Kutner M, Jacobsen DW: Hyperhomocysteinemia confers an independent risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94: 2743-2748, 1996
117. Massy ZA, Chadefaux-Vekemans B, Chevalier A, Bader CA, Drüeke TB, Legendre C, Lacour B, Kamoun P, Kreis H: Hyperhomocysteinaemia: A significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 9: 1103-1108, 1994
118. Hultberg B, Andersson A, Sterner G: Plasma homocysteine in renal failure. Clin Nephrol 40: 230-234, 1993
119. Bostom AG, Shemin D, Lapane KL, Nadeau MR, Sutherland P, Chan J, Rozen R, Yoburn D, Jacques PF, Selhub J, Rosenberg IH: Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 123: 193-202, 1996
120. Födinger M, Mannhalter C, Wölfl G, Pabinger I, Müller E, Schmid R, Hörl W, Sunder-Plassmann G: Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 52: 517-523, 1997
121. Pema AF, Ingrosso D, Galletti P, Zappia V, De Santo NG: Membrane protein damage and methylation reactions in chronic renal failure. Kidney Int 50: 358-366, 1996
122. Tsai C, Perrella MA, Yoshizumi M, Hsien CM, Habe E, Schlagel R, Lee ME: Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 91: 10193-10197, 1992
123. Matthias D, Becker CH, Riezler R, Kindling PH: Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. Atherosclerosis 122: 201-216, 1996
124. Harpel PC, Zhang X, Borth W: Homocysteine and hemostasis: Pathogenetic mechanisms predisposing to thrombosis. J Nutr 126: 1285S-1289S, 1996
125. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ: Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 57: 47-53, 1993
126. Bostom AG, Gohh RY, Beaulieu AJ, Nadeau MR, Hume AL, Jacques PF, Selhub J, Rosenberg IH: Treatment of hyperhomocysteinemia in renal transplant recipients: A randomized, placebo-controlled trial. Ann Intern Med 127: 1089-1092, 1997
127. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR: Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. Metabolism 37: 697-701, 1988
128. Vanholder R, Van Landschoot N, De Smet R, Schools A, Ringoir S: Drug protein binding in chronic renal failure: Evaluation of nine drugs. Kidney Int 33: 996-1004, 1988
129. Depner TA: Suppression of tubular anion transport by an inhibitor of serum protein binding in uremia. Kidney Int 20: 511-518, 1981
130. Lim CF, Bernard BF, de Jong M, Docter R, Krenning EP, Hennemann G: A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab 76: 318-324, 1993
131. Motojima M, Nishijima F, Ikoma M, Kawamura T, Yoshioka T, Fogo AB, Sakai T, Ichikawa I: Role for "uremic toxin" in the progressive loss of intact nephrons in chronic renal failure. Kidney Int 40: 461-469, 1991
132. Niwa T, Ise M: Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 124: 96-104, 1994
133. Henderson SJ, Lindup WE: Renal organic acid transport: Uptake by rat kidney slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uremia. J Pharmacol Exp Ther 263: 54-60, 1992
134. Costigan MG, Lindup WE: Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uremia. Kidney Int 49: 634-638, 1996
135. Mabuchi H, Nakahashi H: Inhibition of hepatic glutathione S-transferases by a major endogenous ligand substance present in uremic serum. Nephron 49: 281-286, 1988
136. Niwa T, Aiuchi T, Nakaya K, Emoto Y, Miyazaki T, Maeda K: Inhibition of mitochondrial respiration by furan carboxylic acid accumulated in uremic serum in its albumin-bound and non-dialyzable form. Clin Nephrol 39: 92-96, 1993
137. Costigan MG, O'Callaghan CA, Lindup WE: Hypothesis: Is accumulation of a furan dicarboxylic acid (3-carboxy-4-methyl-5-propyl-2-furanpropionic acid) related to the neurological abnormalities in patients with renal failure? Nephron 73: 169-173, 1996